EUVIMEDOpdag EUVIMED
Crossref

The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India

Shruti Singh iD, Chanchal Rana iD, Pooja Ramakant iD, Kul Ranjan Singh iD, Anand Mishra iD

Diagnostic Cytopathology · 2025

DOI: 10.1002/dc.70074 ↗

At a glance

Journal article in Diagnostic Cytopathology, 2025. Written by Shruti Singh and 4 co-authors. Institution: Department of Pathology, Hind Institute of Medical Sciences, Lucknow, India. Major MEDLINE topics: Thyroid Neoplasms, Thyroid Nodule, Adenocarcinoma, Follicular. 30 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Thyroid nodules are common in clinical practice, and fine‐needle aspiration cytology (FNAC) remains the primary test for malignancy risk assessment. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) standardizes interpretation and guides management. This study evaluated the distribution of Bethesda categories, risk of neoplasia (RON) and malignancy (ROM), and the impact of non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) on risk stratification.

Methods

A retrospective review of 2578 thyroid FNACs (2016–2024) was conducted at King George's Medical University, Lucknow. Cytological diagnoses were classified using TBSRTC (2017 and 2023). Histopathological correlation was available in 1043 cases (40.5%). RON and ROM were calculated for each category, with ROM assessed before and after excluding NIFTP. Smears were independently reviewed by two cytopathologists, and diagnostic metrics (sensitivity, specificity, accuracy) were derived using histopathology as reference; 95% confidence intervals were estimated by exact binomial methods.

Results

Most cases were Benign (73.2%), followed by Malignant (7.2%) and Follicular Neoplasm (6.1%). Malignancy was confirmed in 245 cases. ROM ranged from 3.7%–9.9% (Benign) to 58.6%–100% (Malignant), showing a progressive rise across categories. Reclassification of NIFTP notably reduced ROM for indeterminate categories (AUS: 43.2% → 31.8%; FN: 40.2% → 28.4%; SM: 52.4% → 42.9%).

Conclusion

TBSRTC reliably stratifies malignancy risk in thyroid nodules. Reclassification of NIFTP has a substantial impact on ROM in indeterminate categories, underscoring the need for precise cytologic‐histologic correlation and regional validation to optimize patient management.

Subjects

MeSH terms (MEDLINE)

Thyroid NeoplasmsThyroid NoduleAdenocarcinoma, FollicularHumansIndiaFemaleMaleBiopsy, Fine-NeedleMiddle AgedRetrospective StudiesAdultRisk AssessmentAgedThyroid GlandYoung Adult

Author keywords

Bethesda systemFNACNIFTPcytopathologyhistopathologyrisk of malignancythyroid nodule

Authors and institutions

  • Department of Pathology, Hind Institute of Medical Sciences, Lucknow, India.
  • Department of Pathology, King George's Medical University, Lucknow, India.
  • Department of Endocrine Surgery, King George's Medical University, Lucknow, India.

ORCID profiles: Shruti Singh, Chanchal Rana, Pooja Ramakant, Kul Ranjan Singh, Anand Mishra

Cite

APA

Singh, S., Rana, C., Ramakant, P., Singh, K. R., & Mishra, A. (2025). The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70074

Vancouver

Singh S, Rana C, Ramakant P, Singh KR, Mishra A. The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India. Diagnostic Cytopathology. 2025. doi:10.1002/dc.70074

BibTeX
@article{Singh2025,
  author = {Singh, Shruti and Rana, Chanchal and Ramakant, Pooja and Singh, Kul Ranjan and Mishra, Anand},
  title = {The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India},
  journal = {Diagnostic Cytopathology},
  year = {2025},
  doi = {10.1002/dc.70074}
}
Start for free →